Our advice for clinicians on the coronavirus is here.
If you are a member of the public looking for information and advice about coronavirus (COVID-19), including information about the COVID-19 vaccine, go to the NHS website. You can also find guidance and support on the GOV.UK website.
Commissioning statement: Ivacaftor, tezacaftor/ivacaftor, lumacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of cystic fibrosis transmembrane conductance regulator (CFTR) mutations within the criteria set out in this commissioning statement.
Clinical Commissioning Urgent Policy Statement: Cystic fibrosis modulator therapies access agreement for licensed mutations
NHS England provides through an access agreement the cystic fibrosis modulator therapies: Ivacaftor; lumacaftor/ivacaftor; and tezacaftor/ivacaftor for patients in England as defined by their marketing authorisations. This updated policy includes access to the triple therapy elexacaftor/tezacaftor/ivacaftor according to the European marketing authorisation and other revisions to the market authorisations for these products since the policy was first published.
Clinical Commissioning Urgent Policy Statement: Ivacaftor and tezacaftor/ivacaftor for cystic fibrosis: “off-label” use in patients with named rarer mutations
NHS England has confirmed ivacaftor and tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of cystic fibrosis transmembrane conductance regulator (CFTR) mutations within the criteria set out in this policy.
In circumstances when NHS England needs to implement a commissioning policy quickly, a Policy Statement or Urgent Policy Statement will be developed. These policy statements have been through the standard development process for all policies, including evidence review, impact analysis and decision by the Clinical Priorities Advisory Group (CPAG), however they have not been subject […]
Respiratory services deal with patients with breathing difficulties. Respiratory disease services are usually provided by respiratory physicians in local hospitals. However, some diseases are very rare while other more common ones can lead to complex problems. Scope This Clinical Reference Group (CRG) covers: services for people with severe and difficult-to-control asthma services for people with […]
NHS England has today (2 July) set out its planned investment decisions for certain specialised services as part of its annual commissioning round. The decision follows a three-month public consultation on the principles and processes NHS England will follow when making investment decisions. Feedback from the consultation has helped inform the way these decisions have […]
NHS England announces major extension of national HIV prevention programme with Public Health England and funding for ten new specialised treatments
NHS England will fund a major extension to the national HIV prevention programme led by Public Health England with the aim of supporting those most at risk and reducing the incidence of HIV infection. It has also decided to routinely commission ten new specialised treatments as part of the annual prioritisation process for specialised treatments. […]
NHS patients in England will be some of the first people in Europe to benefit from a new “truly life-transforming” treatment for cystic fibrosis, health service chief executive Sir Simon Stevens has announced today. Three in five patients with the deadly genetic condition could benefit from the ‘triple combination’ treatment produced by Vertex Pharmaceuticals. This […]
NHS England has today (11 July) set out the results of its annual process for deciding which new treatments and services it will make available to patients. Around a hundred policies were considered over the course of the year. Many of these were considered as ‘In Year Service Developments’ – policies which are cost-saving or […]
The major work programmes mapped out in this Plan are underpinned by an agreed, costed and phased NHS technology plan, building on the recommendations of the Wachter review. It will simplify patient access to care, in the most appropriate location, while supporting people in managing their own health. Specifically, during the coming two years we […]